نتایج جستجو برای: جهش jak2

تعداد نتایج: 7772  

Journal: :European journal of haematology 2007
Thomas Stauffer Larsen Niels Pallisgaard Michael Boe Møller Hans Carl Hasselbalch

BACKGROUND AND OBJECTIVES The JAK2 V617F tyrosine kinase mutation is present in the great majority of patients with polycythemia vera (PV), and approximately half of the patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF). The three distinct disease entities may be considered as three phenotypic presentations of the same JAK2 V617F positive chronic myeloproliferative di...

Journal: :Bosnian journal of basic medical sciences 2016
Guoliang Wang Jingchao Zhang Danhua Dui Haoyuan Ren Jin Liu

The pathogenesis of severe acute pancreatitis (SAP) remains unclear. The Janus kinase and signal transducer and activator of transcription (JAK/STAT) pathway is important for various cytokines and growth factors. This study investigated the effect of the late inflammatory factor high mobility group box 1 (HMGB1) on the activation of JAK2/STAT3 in pancreatic acinar cells and the inhibitory effec...

Journal: :Blood 2014
Rodolphe Besancenot Damien Roos-Weil Carole Tonetti Hadjer Abdelouahab Catherine Lacout Florence Pasquier Christophe Willekens Philippe Rameau Yann Lecluse Jean-Baptiste Micol Stefan N Constantinescu William Vainchenker Eric Solary Stéphane Giraudier

Megakaryopoiesis is a 2-step differentiation process, regulated by thrombopoietin (TPO), on binding to its cognate receptor myeloproliferative leukemia (MPL). This receptor associates with intracytoplasmic tyrosine kinases, essentially janus kinase 2 (JAK2), which regulates MPL stability and cell-surface expression, and mediates TPO-induced signal transduction. We demonstrate that JAK2 and MPL ...

Journal: :PLoS ONE 2006
Virginia M. Zaleskas Daniela S. Krause Katherine Lazarides Nihal Patel Yiguo Hu Shaoguang Li Richard A. Van Etten

BACKGROUND A somatic activating mutation (V617F) in the JAK2 tyrosine kinase was recently discovered in the majority of patients with polycythemia vera (PV), and some with essential thrombocythemia (ET) and chronic idiopathic myelofibrosis. However, the role of mutant JAK2 in disease pathogenesis is unclear. METHODS AND FINDINGS We expressed murine JAK2 WT or V617F via retroviral bone marrow ...

2014
Shih-Min A. Huang Anlai Wang Rita Greco Zhifang Li Fangxian Sun Claude Barberis Michel Tabart Vinod Patel Laurent Schio Raelene Hurley Bo Chen Hong Cheng Christoph Lengauer Jack Pollard James Watters Carlos Garcia-Echeverria Dmitri Wiederschain Francisco Adrian JingXin Zhang

Inhibitors of JAK2 kinase are emerging as an important treatment modality for myeloproliferative neoplasms (MPN). However, similar to other kinase inhibitors, resistance to JAK2 inhibitors may eventually emerge through a variety of mechanisms. Effective drug combination is one way to enhance therapeutic efficacy and combat resistance against JAK2 inhibitors. To identify potential combination pa...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2006
J A Kennedy F Barabé B J Patterson J Bayani J A Squire D L Barber J E Dick

Activation of JAK2 by chromosomal translocation or point mutation is a recurrent event in hematopoietic malignancies, including acute leukemias and myeloproliferative disorders. Although the effects of activated JAK2 signaling have been examined in cell lines and murine models, the functional consequences of deregulated JAK2 in the context of human hematopoietic cells are currently unknown. Her...

Journal: :Cell 1998
Hans Neubauer Ana Cumano Mathias Müller Hong Wu Ulrike Huffstadt Klaus Pfeffer

Janus kinases (Jaks) play an important role in signal transduction via cytokine and growth factor receptors. A targeted inactivation of Jak2 was performed. Jak2-/- embryos are anemic and die around day 12.5 postcoitum. Primitive erythrocytes are found, but definitive erythropoiesis is absent. Compared to erythropoietin receptor-deficient mice, the phenotype of Jak2 deficiency is more severe. Fe...

2017
Tao Shen Zhengming Chen Zhizhuang Joe Zhao Jie Wu

Recognition of major histocompatibility complex (MHC) class I antigens on tumor cells by cytotoxic T cells is involved in T cell-mediated tumor immune surveillance and immune checkpoint therapy. The interferon-γ (IFNγ)-IRF1 signaling pathway regulates MHC class I antigen presentation. To examine genetic defects of the IFNγ-IRF1 pathway in non-small cell lung cancer (NSCLC), we analyzed The Canc...

Journal: :Experimental cell research 2006
Kristen Frenzel Tiffany A Wallace Issam McDoom Hong D Xiao Mario R Capecchi Kenneth E Bernstein Peter P Sayeski

Jak2 is a member of the Janus family of tyrosine kinases and is involved in cytokine signaling. As a part of a study to determine biological functions of Jak2, we used molecular modeling to identify W1038 as a residue that is critical for tyrosine kinase function. Mutation of W1038, in tandem with E1046, generates a dominant-negative form of the Jak2 protein. Mice that were engineered to expres...

Journal: :Blood 2008
Daniela Pietra Sai Li Angela Brisci Francesco Passamonti Elisa Rumi Alexandre Theocharides Maurizio Ferrari Heinz Gisslinger Robert Kralovics Laura Cremonesi Radek Skoda Mario Cazzola

We searched for JAK2 exon 12 mutations in patients with JAK2 (V617F)-negative myeloproliferative disorders. Seventeen patients with polycythemia vera (PV), including 15 sporadic cases and 2 familial cases, carried deletions or duplications of exon 12 in circulating granulocytes but not in T lymphocytes. Two of the 8 mutations detected were novel, and the most frequent ones were N542-E543del and...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید